Navigation Links
Vista Partners Initiates Coverage on Raptor Pharmaceuticals Corp.
Date:10/9/2007

LOS ANGELES, Oct. 9 /PRNewswire/ -- Vista Partners announced today that it has initiated coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP). "Raptor's management team was pivotal in getting two drugs approved and creating stockholder value while at BioMarin Pharmaceutical, a $2.4B biotech company and we believe they will do it again with Raptor," stated Ross Silver, Director of Research at Vista Partners. Vista Partners provides independent, equity research to institutional and individual investors, with a focus on publicly traded small capitalization companies. For more information and to download the report; please visit the Vista Partners website at http://www.vistap.com.

About Raptor:

Raptor Pharmaceuticals Corp.'s (the "Company") sole business is its 100% ownership of Raptor Pharmaceutical Inc., a development stage biotechnology company which bioengineers novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein ("RAP") and related proteins. The Company's preclinical programs target cancer, neurodegenerative disorders, infectious diseases and osteoporosis. HepTide(TM) utilizes engineered RAP-based peptides conjugated to drugs to target their delivery to the liver. In neurodegenerative diseases, engineered RAP peptides called NeuroTrans(TM) are currently undergoing evaluation at Stanford University in cell culture and preclinical models for their ability to enhance the transport of molecules from blood to brain. In osteoporosis, Raptor is testing the ability of WntTide(TM), which are Mesd and engineered Mesd-based peptides and act through LRP5, a known determinant of bone density, to combat osteoporosis and increase bone density. In an effort to protect its novel approach, Raptor currently has five patent applications in review in the U.S., and countries in Europe and Asia, as well as two provisional patent applications licensed from Washington University. In addition, the Company has recently submitted two new provisional patent applications in the U.S., the first of which covers a new family of RAP peptides, with the second application to further support and expand the Company's coverage in specific disease indications.

Contact:

Vista Partners LLC

Ross Silver

(415) 738-6229

info@vistap.com

http://www.vistap.com


'/>"/>
SOURCE Vista Partners LLC
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Evista Not A Cure For Heart Disease
2. Spouses and other partners lower blood pressure says new research
3. Changing Partners may put Expectant Mothers at Risk
4. British Healthcare Mission Explores Partnership Possibilities With Indian Healthcare Sector
5. Partnership Between Diabetes India And Elsevier Announced
6. Betterment Of Health In Case Of Gay And Lesbian Civil Partnerships
7. Private Public Partnership To Tackle TB, In Karnataka
8. Courting HIV through Marriage or Partnership
9. Jealousy In Men Peaks When Partners Are Most Fertile
10. War Trauma Not Passed On To Partners And Children, Study
11. SRM Inst Signs Mou With Partners Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... G.A. (PRWEB) , ... February 09, 2016 , ... ... and grout cleaning and sealing company , is proud to announce that many ... their superior levels of customer service. The hard surface restoration franchises received customer ...
(Date:2/8/2016)... , ... February 08, 2016 , ... CURE Media ... has officially launched the Multiple Myeloma Heroes Awards event , which will annually ... the lives of patients with MM. The MM Heroes Awards nomination process ...
(Date:2/8/2016)... ... February 08, 2016 , ... Stephanie ... celebrates the beginning of a new charity campaign. As part of their ongoing ... Advocates (CASA). In the belief that children deserve a voice, and in the ...
(Date:2/8/2016)... New York, NY (PRWEB) , ... February 08, 2016 , ... ... handles are too much to handle, you are not alone. According to the Center ... conditions include heart disease, stroke, type 2 diabetes and certain types of cancer, some ...
(Date:2/8/2016)... ... February 08, 2016 , ... Local insurance agency Dennis ... FL area, has initiated a fundraiser for a two year old little girl ... after Christmas. To support this beautiful child who is facing life’s journey without ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... KONG , Feb. 9, 2016 Athenex, Inc. ... Athenex as Vice President of Corporate Strategy and Business Development ... MSc, MBA has joined as Senior Director and Deputy Head of Clinical ... . Simon Pedder stated, "Athenex has ... for a while. Coupled together with their unique business model ...
(Date:2/9/2016)... 2016  The Parenteral Drug Association, Inc. (PDA), ... manufacturing sterile drug products, today announced the publication ... – With link to Comparison Spreadsheet. The ... U.S. FDA, the EU, the Pharmaceutical Inspection Convention/Scheme ... --> --> PDA,s Global Sterile ...
(Date:2/8/2016)... 2016 Respiratory Devices - Medical Devices ... Devices sector report, " Respiratory Devices - Medical ... of Respiratory Devices currently in pipeline stage. ... products with comparative analysis of the products at ... players involved in the pipeline product development. It ...
Breaking Medicine Technology: